```html

Immune Thrombocytopenic Purpura (ITP) – A Patient‑Friendly Medical Guide

Overview

Immune thrombocytopenic purpura (ITP) is an acquired blood disorder in which the immune system mistakenly attacks and destroys platelets – the tiny cell fragments that help blood clot. The result is a reduced platelet count (thrombocytopenia) that can cause easy bruising, bleeding, and in severe cases, life‑threatening hemorrhage.

ITP can appear at any age, but it follows a bimodal distribution:

• Children: Often follows a viral infection and is usually acute, lasting weeks to months.
• Adults: More often chronic, persisting >12 months, and more common in women (≈ 2‑3 × higher risk).

Worldwide prevalence is estimated at 23–46 cases per 100,000 people, with about 1 – 2 % of the population experiencing ITP at some point in their lives [Mayo Clinic, 2024]. Although it is a rare disease, because platelet counts can drop dramatically, timely recognition and management are critical.

Symptoms

Symptoms result from the low platelet count and can vary from mild to severe. Not all patients experience every sign.

Bleeding‑related manifestations

• Petechiae: Tiny red or purple spots (1–2 mm) on the skin, often on the lower legs.
• Purpura: Larger 3–10 mm bruises that appear without trauma.
• Ecchymoses: Large, irregular bruises, sometimes spanning several centimeters.
• Nosebleeds (epistaxis): Frequent or prolonged.
• Bleeding gums: Especially after brushing.
• Heavy menstrual bleeding (menorrhagia): Common in women of reproductive age.
• Hematuria: Pink or red urine indicating urinary tract bleeding.
• Melena or hematochezia: Dark tarry stools or bright red blood per rectum, suggesting gastrointestinal bleeding.
• Prolonged bleeding after minor cuts or dental work.

Systemic or nonspecific symptoms

• Fatigue or feeling “run down.”
• Headache or dizziness, especially if bleeding is internal.
• Unexplained bruising on the arms, torso, or face.

Severe, life‑threatening signs (require immediate care)

• Intracranial hemorrhage – sudden severe headache, confusion, seizures, or loss of consciousness.
• Profuse gastrointestinal bleeding – vomiting blood or passing large amounts of blood.
• Bleeding into the eye (vitreous hemorrhage) causing sudden vision loss.

Causes and Risk Factors

ITP is an autoimmune condition, but the precise trigger is often unknown. The immune system produces antibodies that bind to platelet surface proteins (e.g., GPIIb/IIIa), marking them for destruction in the spleen and elsewhere.

Potential triggers

• Infections: Common in children – e.g., Epstein‑Barr virus, cytomegalovirus, HIV, hepatitis C.
• Medications: Heparin, quinine, certain antibiotics (e.g., vancomycin), and antiepileptics have been implicated.
• Vaccines: Rarely, the MMR vaccine or COVID‑19 vaccines have been temporally associated with ITP (incidence <0.1 %); benefits still outweigh risks.
• Other autoimmune diseases: Systemic lupus erythematosus, rheumatoid arthritis, and thyroiditis increase risk.
• Pregnancy: Hormonal changes can exacerbate underlying ITP.

Risk factors

• Female sex (especially ages 20‑40).
• Personal or family history of autoimmune disease.
• Recent viral infection or certain drug exposures.
• Underlying immunodeficiency (e.g., HIV).

Diagnosis

Diagnosing ITP is primarily one of exclusion – other causes of thrombocytopenia must be ruled out.

Initial evaluation

• Complete Blood Count (CBC): Confirms low platelet count, usually <150 × 10⁹/L; white blood cells and hemoglobin are typically normal.
• Peripheral Blood Smear: Checks platelet size (often larger “young” platelets) and rules out abnormal cells that suggest leukemia or marrow disease.
• Medical History & Physical Exam: Looks for recent infections, medication use, bruising patterns, and splenomegaly.

Additional tests when needed

• Bone Marrow Aspiration/Biopsy: Reserved for atypical presentations (e.g., age > 60, unexplained anemia, or when other marrow disorders are suspected).
• Coagulation Panel (PT/INR, aPTT): Typically normal in ITP, helping differentiate from disseminated intravascular coagulation.
• HIV, Hepatitis C, and H. pylori Screening: Because chronic infection can cause secondary thrombocytopenia.
• Autoimmune Panel: ANA, anti‑dsDNA, thyroid antibodies if an associated autoimmune disease is suspected.

Diagnostic criteria (per American Society of Hematology, 2023)

1. Platelet count < 100 × 10⁹/L on at least two separate occasions.
2. No other identifiable cause of thrombocytopenia.
3. Exclusion of drug‑induced thrombocytopenia and marrow infiltration.

Treatment Options

Treatment aims to raise the platelet count to a safe level, reduce bleeding risk, and minimize drug side effects. Decisions are individualized based on platelet count, symptoms, and patient preferences.

First‑line therapies

• Corticosteroids (Prednisone, Dexamethasone): Reduce antibody production; initial response in ~70 % of adults. Typical regimen: Prednisone 1 mg/kg daily for 4–6 weeks or high‑dose Dexamethasone 40 mg daily for 4 days (repeat as needed).
• Intravenous Immunoglobulin (IVIG): Provides rapid, short‑term platelet rise (often within 24–48 h). Used for severe bleeding or when steroids are contraindicated.
• Anti‑D immunoglobulin (Rh‑Ig): Effective only in Rh‑positive, non‑splenectomized patients; works by “distracting” the spleen.

Second‑line / chronic management

• Thrombopoietin Receptor Agonists (TPO‑RAs):
  • Eltrombopag (Orlack) – oral, start 50 mg daily; monitor liver function.
  • Romiplostim (Nplate) – subcutaneous weekly injection.
  Both raise platelet production and have response rates >80 % in refractory ITP [NIH, 2024].
• Rituximab: Anti‑CD20 monoclonal antibody depletes B‑cells; gives durable remission in ~30‑40 % of treated adults.
• Splenectomy: Surgical removal of the spleen eliminates the primary site of platelet destruction. Provides long‑term remission in ~60‑70 % of patients, but carries lifelong infection risk; generally reserved after failed medical therapy.
• Immunosuppressants: Azathioprine, Mycophenolate mofetil, or Cyclosporine may be used when other agents fail.

Supportive & lifestyle measures

• Avoid aspirin, NSAIDs, and other antiplatelet drugs unless medically necessary.
• Use a soft‑bristled toothbrush and electric razor to reduce gum bleeding.
• Wear protective gear (helmets, padded gloves) for high‑impact activities.
• Maintain adequate folic acid and vitamin K intake via diet.

Living with Immune Thrombocytopenic Purpura (ITP)

While ITP can be chronic, many people lead active, fulfilling lives with appropriate management.

Monitoring

• Regular CBC checks – frequency depends on stability (e.g., every 2–4 weeks during medication titration, then every 3–6 months).
• Track bleeding symptoms in a journal; note any new bruises, nosebleeds, or menstrual changes.
• Vaccinations: Stay up‑to‑date, especially pneumococcal, meningococcal, and annual influenza vaccines if you have had a splenectomy.

Daily tips

• Oral hygiene: Floss gently, use a non‑alcoholic mouthwash.
• Skin care: Use moisturizer to avoid skin tears; trim fingernails short.
• Exercise: Low‑impact activities (walking, swimming, yoga) are safe; avoid contact sports if platelet count < 30 × 10⁹/L.
• Travel: Carry a medical alert card indicating ITP and current medications; bring a small supply of emergency IVIG or steroids if you have a history of severe bleeding.
• Pregnancy planning: Discuss with a hematologist and OB‑GYN; most medications (e.g., corticosteroids, IVIG) are safe, while some (e.g., rituximab) require timing considerations.

Emotional wellbeing

Living with a chronic blood disorder can cause anxiety about bleeding or medication side effects. Consider:

• Joining ITP support groups (e.g., ITP Support International).
• Speaking with a mental‑health professional experienced in chronic illness.
• Practicing stress‑reduction techniques such as mindfulness or gentle yoga.

Prevention

Because ITP is largely autoimmune, there is no guaranteed way to prevent it. However, risk can be mitigated:

• Prompt treatment of infections; use vaccines as recommended.
• Avoid unnecessary exposure to drugs known to trigger thrombocytopenia (e.g., quinine, certain antibiotics).
• Maintain a healthy immune system—balanced diet, regular exercise, adequate sleep.
• If you have an existing autoimmune condition, keep it well‑controlled with your specialist.

For patients with a known history of ITP, early discussion with a hematologist before starting new medications or undergoing invasive procedures is essential.

Complications

When left untreated or poorly controlled, ITP can lead to serious outcomes:

• Severe bleeding: Intracranial, gastrointestinal, or intra‑ocular hemorrhage – potentially fatal.
• Chronic fatigue and anemia: Resulting from repeated blood loss.
• Refractory disease: Some patients become resistant to multiple therapies, necessitating splenectomy or experimental agents.
• Infection risk after splenectomy: Encapsulated bacteria (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis) can cause overwhelming sepsis.
• Medication side effects: Long‑term steroids cause osteoporosis, glucose intolerance, weight gain; TPO‑RAs may cause liver enzyme elevations or rare thrombotic events.

When to Seek Emergency Care

References

• Mayo Clinic. “Immune thrombocytopenic purpura (ITP).” Updated 2024. https://www.mayoclinic.org/diseases-conditions/itp
• American Society of Hematology. “Guidelines for the Management of ITP.” 2023. https://www.ash.org
• National Institutes of Health (NIH). “Thrombocytopenia.” 2024. https://www.nhlbi.nih.gov/health
• Centers for Disease Control and Prevention (CDC). “Vaccines and ITP.” 2023. https://www.cdc.gov/vaccinesafety/concerns/itp.html
• Cleveland Clinic. “Immune Thrombocytopenic Purpura (ITP) Treatment.” 2024. https://my.clevelandclinic.org/health/diseases/17214-immune-thrombocytopenic-purpura-itp

```